Slide 1: Investor Education Event: ESG Performance Report
19 March 2024 Investor Education Event: ESG Performance Report 19 March 2023 gsk.com
Slide 2: Today's speakers
Today’s speakers Clare Griffin Claire Lund VP, Reputation & VP, Sustainability Responsible Business 2
Slide 3: How ESG fits into GSK's overall strategy
How ESG fits into GSK’s overall strategy We unite science, talent and technology to get ahead of disease together Purpose Health impact + Shareholder returns + Thriving people We prevent and treat disease with vaccines, specialty and general medicines Strategy R&D focused on the science of the immun
Slide 4: ESG performance to deliver health impact and shareholder returns
ESG performance to deliver health impact and shareholder returns Six focus areas addressing what is most material to our business and stakeholders Sustainable performance and long-term growth Access Environment Trust for all stakeholders Global health and Product governance Health security Reduced r
Slide 5: Embedding ESG delivery and measurement
Embedding ESG delivery and measurement Corporate Responsibility Committee (CRC) GSK Leadership Team • Board level Committee • Individual accountabilities aligned to six focus areas, as relevant • Oversees ESG priorities, provides guidance and reviews performance • Ensures effective framework to mana
Slide 6: Overall ESG Performance Rating
Overall ESG Performance Rating Integrates ESG into strategy delivery; measures and verifies progress • Rating is one of our corporate KPIs and measures progress against the 22 key 2023 ESG Performance Rating metrics aligned to each of our six focus areas • On track, based on 95% of all performance m
Slide 7: External benchmarking
External benchmarking Top quartile performance in key ESG ratings frequently asked about by investors ESG rankings ESG ratings Access to Medicines Index 1st the index Sustainalytics Low risk (16.7) Antimicrobial Resistance Leading pharma company MSCI AA Benchmark Moody’s ESG solutions Score 62/100 S
Slide 8: 2023 performance highlights across our six focus areas
2023 performance highlights across our six focus areas 8
Slide 9: Access
Access Our commitment We aim to positively impact the health of 2.5 billion people by Make our products available at value-based the end of 2030. We will do this by making our vaccines and prices that are sustainable for our business medicines available as widely as possible, through responsible and
Slide 10: Global health and health security
Global health and health security Our commitment We want to help address the biggest health challenges faced by Develop novel products and technologies to people around the world treat and prevent priority diseases, including pandemic threats We are putting our unique R&D and scientific expertise to
Slide 11: Diversity, equity and inclusion
Diversity, equity and inclusion Our commitment We want to ensure our people can thrive, foster diversity in our clinical trials and support diverse communities, as Enhance recruitment of diverse patient populations in our clinical becoming a more inclusive business is central to our purpose trials;
Slide 12: Ethical standards
Ethical standards Our culture guides our people to behave in an ethical way, Our commitment to do the right thing and Speak Up about any concerns they Promote ethical behaviour across our business by supporting have. our employees to do the right thing and working with suppliers that share our stand
Slide 13: Product governance standards
Product governance standards To protect our patients, it is critically important to ensure the Our commitment quality, safety and reliable supply of our products. Commit to maintaining robust quality and safety processes, and using data and new technologies responsibly Have systems in place that ens
Slide 14: Environment
Environment 2030 targets (using 2020 as baseline) Net zero impact on climate Contributing to a nature positive world • 100% imported renewable electricity by 2025 and Freshwater Oceans 100% renewable electricity (imported and • 100% of marine-derived materials • 100% of our sites to achieve good wat
Slide 15: Operational emissions: 7% overall footprint
Operational emissions: 7% overall footprint Reduced Scope 1 and 2 carbon emissions by 10% in 2023; down 27% since 2020 Renewable electricity Electric vehicles Energy reductions • Member of RE100 • Member of EV100 • Energy efficiency programmes • Reached 83% imported • Plug-in-hybrid or fully electri
Slide 16: Indirect emissions: 93% overall footprint
Indirect emissions: 93% overall footprint Scope 3 emissions increased 4% in 2022 vs. 2021* driven by MDI sales; down 10% compared to 2020 Supply chain emissions Patient use Logistics • 31% of overall footprint • 57% of overall footprint • 4% of overall footprint • Sustainable Procurement • Investing
Slide 17: Freshwater: Targets and action
Freshwater: Targets and action 100% of our sites achieve good Water neutral in operations and Zero impact active water stewardship by 2025 and with key suppliers in water- pharmaceutical ingredient reduce overall water use by 20% stressed regions by 2030 levels for all our sites and key by 2030 supp
Slide 18: Land: Targets and action
Land: Targets and action Positive impact on biodiversity at 100% of agricultural and forestry derived materials sustainably all sites1 by 2030 sourced and deforestation free by 2030 • Completed baseline biodiversity • Sustainable Sourcing Standard outlines the environmental, social and ethical asses
Slide 19: Oceans: Targets and action
Oceans: Targets and action 100% of marine-derived materials sustainably sourced by 2030 • Marine Sustainable Sourcing Standard outlines the environmental, social and ethical requirements which must be met by 2030 for each supply chain to be considered sustainably sourced • For example, we use horses
Slide 20: Atmosphere: Action
Atmosphere: Action Taking action on air pollution Air pollution footprint • Members of the Alliance for • Completed an initial assessment to establish an air pollution footprint in our Clean Air through the Clean Air operations and our supply chain Fund (CAF) and the World Economic Forum • Creating
Slide 21: Waste and Materials: Targets and action
Waste and Materials: Targets and action Zero operational waste, 10% waste reduction 25% environmental impact reduction including eliminating single from supply chain by 2030 for our products and packaging by 2030 use plastics1 by 2030 • For our supply chain, working • Embedding eco-design principles
Slide 22: ESG resources
ESG resources Links to latest reports from 2023 • Annual Report • Responsible business section only from Annual Report • ESG Performance Report • Materiality assessment • Our Contribution to the SDGs 19 March 2024 22
Slide 23: Q&A
Q&A 23